Ketamine Treatment of Youth Suicide Attempters

This double-blind, placebo-controlled trial (n=140) investigates the efficacy and safety of ketamine in rapidly reducing severe suicide risk among youth aged 14-30 who have attempted suicide.

Conducted by Tatiana Falcone, MD, at The Cleveland Clinic and Massachusetts General Hospital, the study aims to address the critical need for fast and effective treatments in this high-risk age group.

Participants will be randomly assigned to receive either ketamine or saline infusions while admitted to inpatient psychiatry. Weekly sessions of Collaborative Assessment for the Management of Suicidality (CAMS) will also be conducted.

The primary outcome measure is the rate of remission of suicidal symptoms at the end of treatment, with secondary measures including the number of CAMS sessions needed to achieve enduring mental stability and changes in the Beck Scale for Suicidal Ideation score.

The study, expected to complete enrolment by June 2024, is funded by the National Institutes of Health (NIH) and is a phase III intervention trial.

Topic Suicidality Adolescence and Psychedelics
Compound Ketamine Placebo
Country United States of America
Visit trial

Trial Details



Trial Number

Sponsors & Collaborators

The Cleveland Clinic
This company doesn't have a full profile yet, it is linked to a clinical trial.

Massachusetts General Hospital
Massachusettes General Hospital has launched the MGH Center for the Neuroscience of Psychedelics. The announcement has now been done via YouTube, and the formal launch will be in fall 2020.

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.